US Supply of Only Dengue Vaccine to End in Coming Months
WASHINGTON – The United States is poised to lose its sole commercially available dengue vaccine,Qdenga,manufactured by Takeda,as the company plans to discontinue supply in the coming months. The decision, announced this week, leaves public health officials scrambling to address potential outbreaks and protect vulnerable populations, particularly travelers to dengue-endemic regions.
Dengue fever, a mosquito-borne viral infection, affects an estimated 500 million people globally each year, according to the World Health Association. While typically mild, it can develop into severe dengue, a possibly life-threatening complication. The US has seen a meaningful increase in locally acquired dengue cases in recent years, including outbreaks in florida and Texas. The loss of Qdenga removes a crucial preventative tool, impacting travelers and potentially complicating control efforts within the US territories and states experiencing rising infection rates.
Qdenga received FDA approval in December 2023 for use in individuals aged 9 through 45 years living in or traveling to areas with endemic dengue. The vaccine demonstrated approximately 80% efficacy in preventing symptomatic dengue in clinical trials.
“This is certainly concerning news,” said Dr. Peter Hamer, a professor of infectious diseases at Georgetown University, in an interview with healio. “Having a vaccine available is a significant step forward in protecting individuals from this debilitating disease.” Dr. Hamer disclosed research funding from Merck and Sanofi, and research funding and advisory roles with takeda.
Takeda cited “evolving global landscape” and “commercial considerations” as reasons for the discontinuation of supply to the US, though the vaccine will remain available in othre countries. Dr. Jay Petersen, also speaking with Healio, reported no relevant financial disclosures.
The CDC is currently assessing the implications of Takeda’s decision and working to ensure continued access to dengue prevention strategies, including mosquito control and personal protective measures. The agency recommends travelers consult with healthcare providers regarding appropriate precautions before visiting dengue-prone areas.
